VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
OABI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
OABIOmniAb, Inc.
$4.66$555M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
OABI logo

OmniAb, Inc.

OABI
NASDAQ · Biotechnology
$4.66
At close - Oct 23, 4:00 PM EDT - USD
Market Cap$555M
P/E-8.2x
52W High$5.43
Volume1.28M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Revenue Recovery Masks Persistent Cash Burn and Equity Erosion

OmniAb's revenue has rebounded sharply from a 2025 trough, with Q2 2026 revenue of $13.4 million suggesting a return to a high-margin, asset-light model. However, this recovery is overshadowed by a persistent operating cost structure that generated a -$6.6 mil...

GrowthAccelerating
ProfitabilityStrained
ValuationReview
TechnicalsHealthy
Explore valuation models
MARKET ACTION

OABI price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-120% Peers

P/E is 120% below peer median

03

Market leadership

RS 98 · Leader

High momentum (Outperforming 98% of market)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystConfirmed earnings · Oct 30

Market performance

Price History →

Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
OABI+147.87%
S&P 500 (^GSPC)+11.24%
1-Year Return
OABI+191.25%
S&P 500 (^GSPC)+13.13%
3-Year Return
OABI-1.06%
S&P 500 (^GSPC)+77.00%
5-Year Return
OABI-53.18%
S&P 500 (^GSPC)+63.63%

Growth & profitability

Annual revenue & EPS trend
Revenue
$19M-29.3% YoY
Net income
-$65M-4.4% YoY
Free cash flow
-$37M+10.9% YoY
Operating margin
-383.1%-100.8 pts YoY
ROIC (TTM)-19.7%
Avg ROIC 5Y-
ROE (TTM)-23.4%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (42%)
Revenue Beat Rate4/12 (33%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 6, 2026
-$0.05+58.3%
vs -$0.12
$13M+185.9%
vs $5M
Q2 2026
May 7, 2026
-$0.06+40.0%
vs -$0.10
$14M+157.6%
vs $6M
Q2 2026
Mar 4, 2026
-$0.11-37.5%
vs -$0.08
$8M-7.0%
vs $9M
Q4 2025
Nov 4, 2025
-$0.14-2.9%
vs -$0.14
$2M-60.3%
vs $6M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
Business Wire·Oct 14, 2026
OmniAb to Report Third Quarter 2026 Financial Results on October 30

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Friday, October 30, 2026, and will hold a conference call that same day beginning at 8:00 a.m. Eastern time. Conference Call and Webcast What:   OmniAb conf.

MarketBeat·Oct 7, 2026
OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth

OmniAb NASDAQ: OABI used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market through its newly introduced OmniTides platform.

Seeking Alpha·Oct 6, 2026
OmniAb, Inc. (OABI) Analyst/Investor Day Transcript

OmniAb, Inc. (OABI) Analyst/Investor Day Transcript

Zacks Investment Research·Oct 6, 2026
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy

OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Filtered for OmniAb, Inc.More Headlines
04

Compare before deciding

Benchmark OABI against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for OmniAb, Inc. (OABI)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
OABI logoOABIOmniAb, Inc.Current
$4.66$554.96M-8.18-29.27%-347.04%-23.36%—
HALO logoHALOHalozyme Therapeutics, Inc.
$125.63$14.9B49.0737.55%24.86%180.63%—
ADCT logoADCTADC Therapeutics S.A.
$1.44$183.16M-1.2914.85%-123.03%——
RCUS logoRCUSArcus Biosciences, Inc.
$18.54$2.33B-5.64-4.26%-386.32%-87.98%—
IMVT logoIMVTImmunovant, Inc.
$28.41$5.86B-10.26—-7585.86%-69.59%—
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$805.02$82.93B19.410.99%27.86%18.49%—

Compare OABI vs Peers

OmniAb, Inc. (OABI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HALO

Most directly comparable listed peer for OABI.

Scale Benchmark

vs TMO

Larger-name benchmark to compare OABI against a more recognizable public peer.

Peer Set

Compare Top 5

vs HALO, ADCT, RCUS, IMVT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

OABI SEC Filings & Documents

OmniAb, Inc. (OABI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 6, 2026·SEC

Material company update

Jul 13, 2026·SEC

Material company update

Jun 18, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 4, 2026·SEC

FY 2025

Mar 18, 2025·SEC

FY 2024

Mar 25, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 6, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 4, 2025·SEC

Get notified when OABI posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

OABI Frequently Asked Questions

OmniAb, Inc. (OABI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is OmniAb, Inc.'s revenue?

OmniAb, Inc. (OABI) reported $38.4M in revenue for fiscal year 2025. This represents a 110% increase from $18.3M in 2019.

How fast is OmniAb, Inc. growing?

OmniAb, Inc. (OABI) saw revenue decline by 29.3% over the past year.

Is OABI profitable?

OmniAb, Inc. (OABI) reported a net loss of $44.3M for fiscal year 2025.

Dividend & Returns
What is OABI's return on equity?

OmniAb, Inc. (OABI) has a return on equity (ROE) of -23.4%. Negative ROE indicates the company is unprofitable.

What is OmniAb, Inc.'s free cash flow?

OmniAb, Inc. (OABI) had negative free cash flow of $18.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in OABI back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →